Kewalramani Reshma's Form 4 filing
Vertex Pharmaceuticals IncVRTX · filed Nov 10, 2026
- Accession no.
- 0000875320-26-000293
- Filed
- Nov 10, 2026, 4:20 PM ET
- Trade date
- Nov 6, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $6.31M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kewalramani ReshmaCIK 0001735944 | Director, Officer (CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Common Stock | SSaleDisposed | −11,866 | $531.53 | −$6,307,134.98 | 86,471 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.